AstraZeneca and Summit Therapeutics also signed a memorandum of understanding to launch a global development program ...
Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company, announced updated Phase 1 clinical data for IBI3003 in patients with relapsed or refractory multiple myeloma (R/R MM), presented orally ...
Shanghai RAAS, a leading Chinese blood products company, plans to acquire 100% equity in Boehringer Ingelheim's CDMO facility in Shanghai's ...
Explore how new cholesterol-lowering therapies, including PCSK9 inhibitors and oral options, are changing the landscape of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results